TCL CSOT Unveils “2025 Eye-Care Technology White Paper”, Setting New Benchmarks for Natural-Light Display Standards
SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- TCL China Star Optoelectronics Technology (TCL CSOT), a global leader in advanced display technologies and a subsidiary of TCL Technology (000100.SZ), in collaboration with the National Engineering Research Center for Ophthalmology & Optometry of Wenzhou Medical University in China, and leading industry partners including Lenovo,...
Mazdutide 9mg Supplementary Application Accepted for Review by China’s NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the supplementary application for the 9 mg dosage of mazdutide, an innovative glucagon (GCG)/ glucagon-like peptide-1 (GLP-1) dual receptor...
FROM MEDICAL SUPPLIER TO MULTI-INDUSTRY LEADER: LIVINGSTONE INTERNATIONAL’S UNIQUE GROWTH STRATEGY
SYDNEY, Nov. 25, 2025 /PRNewswire/ -- One of Australia's largest medical supply companies is celebrating its unique warehousing and supply chain strategy that has seen it grow into a leading manufacturer, importer, and supplier to more than 20 key industries. 'One of seven Livingstone warehouses driving Australia’s most reliable supply network.' Livingstone International supplies more...
HKeyBio Launches the HKEY-AIDMD 3.0–a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization
The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platform for evaluating multi-target combination therapies. The HKEY-AIDMD 3.0 omics database integrates spatiotemporal single-cell and spatial omics across various tissues and immune systems...
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN) BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow, and blood FLORENCE, Italy and NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international...
Alzheimer’s Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Results Underscore Need for Continued Research and Diverse Treatment Pipeline CHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. The studies tested an oral semaglutide pill for the treatment of early-stage symptomatic...
The Volpi Rosse Menarini: The ‘Fantastic Ten’ are ready for the 2025 – 2026 Season
Italian wheelchair basketball team, sponsored by Menarini, was presented to the press and public in Italy. The challenges they will be facing in the Italian Serie A and Eurocup 3 are already on the horizon FLORENCE, Italy, Nov. 24, 2025 /PRNewswire/ -- Ten international talents, differing in both age and experience but...
ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered...
Pinnacle Food Announces New Strategic Initiative to Expand its Smart Agriculture Innovation Platform
VANCOUVER, BC, Nov. 24, 2025 /PRNewswire/ -- Pinnacle Food Group Limited (NASDAQ:PFAI) announced a strategic initiative to establish a bioengineering and testing laboratory. The Company is exploring applied bioengineering initiatives to further expand its smart agriculture innovation platform into bioengineering applications, supporting its future growth. To support the lab's development, Pinnacle Food Inc., a...
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), as...
